Loading…
AtriCure, Inc. is projected to rise to $40.32 by 2027, a +18% move from its current price of $34.28. ATRC is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $33.39 | $34.30 | $35.24 | +0.06% |
| Jul 14 | $33.03 | $34.32 | $35.66 | +0.13% |
| Jul 15 | $32.77 | $34.34 | $35.99 | +0.19% |
| Jul 16 | $32.56 | $34.37 | $36.28 | +0.25% |
| Jul 17 | $32.37 | $34.39 | $36.53 | +0.31% |
| Jul 18 | $32.20 | $34.41 | $36.77 | +0.38% |
| Jul 19 | $32.05 | $34.43 | $36.99 | +0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $32.05 | $34.43 | $36.99 | +0.44% |
| Week 2 | $31.25 | $34.58 | $38.27 | +0.88% |
| Week 3 | $30.68 | $34.73 | $39.32 | +1.33% |
| Week 4 | $30.23 | $34.89 | $40.26 | +1.77% |
| Week 5 | $29.86 | $35.04 | $41.12 | +2.22% |
| Week 6 | $29.53 | $35.19 | $41.94 | +2.67% |
| Week 7 | $29.25 | $35.35 | $42.72 | +3.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It markets and sells its products through independent distributors and direct sales personnel.
The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Its product portfolio includes Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments.
The company markets its products through independent distributors and direct sales personnel and is headquartered in Mason, Ohio.
AtriCure, Inc. is currently priced at $34.56, with a market capitalization of $1.75B. It holds a rank of 2160 in its market segment. The current price and market position are complemented by a multi-year forecast that shows upside potential, with the average price projected to rise from $34.56 in 2026 to $348.03 by 2050, and a sequence of increasing averages in between.
The forecast includes neutral near-term sentiment in 2026, turning bullish in the latter years as averages advance.
A major floor 33.3% below — a decisive break under it would weaken the trend.
The nearest floor, 24.6% below — buyers have tended to step in here.
Price is pressing into resistance (0.8% away) — a breakout level to watch.
A major ceiling 17.5% above — clearing it would confirm fresh momentum.
Key ATRC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ATRC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $33.54 | Buy | $33.40 | Buy |
| MA 10 | $31.61 | Buy | $32.09 | Buy |
| MA 20 | $29.92 | Buy | $30.63 | Buy |
| MA 50 | $28.58 | Buy | $29.49 | Buy |
| MA 100 | $29.14 | Buy | $30.16 | Buy |
| MA 200 | $33.07 | Buy | $31.60 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 70.74 | Sell |
| Stoch RSI (14) | 92.05 | Sell |
| CCI (20) | 143.79 | Buy |
| Williams %R (14) | -4.26 | Info |
| MACD (12,26,9) | 0.62 | Buy |
| ROC (12) | 20.53 | Buy |
| Bollinger %B (20,2) | 0.97 | Neutral |
| Stochastic %K (14) | 95.74 | Sell |
| TRIX (15) | 0.46 | Buy |
| Awesome (5,34) | 4.65 | Buy |
| Ultimate (7,14,28) | 85.18 | Sell |
| Momentum (10) | 6.15 | Buy |
| Aroon Osc (25) | 96.00 | Buy |
| Hull MA (9) | 35.09 | Sell |
| ADX (14) | 19.76 | Neutral |
| ATR (14) | 0.78 | Info |
The 30-day technical picture shows bullish sentiment, with RSI14 at 70. The stock trades near key levels, with a SMA50 of $28.47 and a SMA200 of $33.09. Support is listed at $25.86 and resistance at $34.56, framing a near-term path shaped by these technical anchors.
The 30-day price range runs from a low of $28.76 to a high of $41.53, indicating a reasonably wide swing in the near term while staying above recent support levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $25.86 | $34.28 | $47.67 | 0% | Neutral | |
| $32.13 | $40.32 | $53.52 | +18% | Neutral | |
| $35.60 | $45.94 | $63.25 | +34% | Bullish | |
| $39.72 | $52.43 | $74.29 | +53% | Bullish | |
| $42.94 | $57.84 | $83.97 | +69% | Bullish | |
| $54.81 | $75.19 | $111.48 | +119% | Bullish | |
| $61.68 | $86.09 | $130.07 | +151% | Bullish | |
| $64.81 | $91.92 | $141.28 | +168% | Bullish | |
| $71.97 | $103.64 | $161.83 | +202% | Bullish | |
| $69.10 | $100.98 | $159.99 | +195% | Bullish | |
| $115.72 | $180.68 | $304.37 | +427% | Bullish | |
| $206.36 | $361.05 | $665.11 | +953% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $25.86 | $34.28 | $42.22 | +0.00% |
| August 2026 | $30.65 | $36.16 | $43.80 | +5.48% |
| September 2026 | $30.55 | $36.30 | $44.46 | +0.38% |
| October 2026 | $31.46 | $37.60 | $46.48 | +3.59% |
| November 2026 | $32.17 | $38.65 | $48.15 | +2.79% |
| December 2026 | $31.48 | $37.99 | $47.67 | -1.70% |
Click any year to see its month-by-month ATRC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
AtriCure, Inc.'s 2026 outlook centres on $34.28, within a $25.86 to $47.67 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, ATRC could reach as high as $53.52, with a base case around $40.32 and support toward $32.13 — roughly +18% from $34.28. Price action looks broadly range-bound.
Expect ATRC to range from $35.60 to $63.25 through 2028. The $45.94 average target implies a +34% move from current prices. That is up +14% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The ATRC price prediction for 2029 points to an average of $52.43 (low $39.72, high $74.29) — a potential gain of +53% on today's $34.28. Momentum favours further upside here.
In 2030, ATRC is projected to trade between $42.94 and $83.97, averaging $57.84 — a potential gain of +69% from today's $34.28. That is up +10% on the projected 2029 average. Buyers look set to stay in control over this stretch.
AtriCure, Inc.'s 2031 outlook centres on $75.19, within a $54.81 to $111.48 range. That is up +30% on the projected 2030 average. That marks a +119% change versus current levels. Momentum favours further upside here.
By 2032, ATRC could reach as high as $130.07, with a base case around $86.09 and support toward $61.68 — roughly +151% from $34.28. Buyers look set to stay in control over this stretch.
Expect ATRC to range from $64.81 to $141.28 through 2033. The $91.92 average target implies a +168% move from current prices. That is up +7% on the projected 2032 average. Momentum favours further upside here.
The ATRC price prediction for 2034 points to an average of $103.64 (low $71.97, high $161.83) — a potential gain of +202% on today's $34.28. Buyers look set to stay in control over this stretch.
In 2035, ATRC is projected to trade between $69.10 and $159.99, averaging $100.98 — a potential gain of +195% from today's $34.28. That is -3% versus the projected 2034 average. Momentum favours further upside here.
AtriCure, Inc.'s 2040 outlook centres on $180.68, within a $115.72 to $304.37 range. That is up +79% on the projected 2035 average. That marks a +427% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, ATRC could reach as high as $665.11, with a base case around $361.05 and support toward $206.36 — roughly +953% from $34.28. Momentum favours further upside here.
Investing $1,000 in ATRC today (≈ 29.171529 ATRC) could be worth
$10,532.4
+$9,532.4 (+953%) by 2050 · US Dollar
Based on the average projected ATRC price of $361.05 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ATRCwould be worth at today's price.
$1,000 invested in ATRC on Jul 10, 2025 (≈ 31.191515 ATRC) would be worth
$1,069.25
+$69.25 (+6.9%) today · 1.07× · US Dollar
Based on a ATRC entry price of $32.06 vs. today's $34.28.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $31.79 | $1,078.33 | +7.8% |
| 1 month ago | $27.51 | $1,246.09 | +24.6% |
| 3 months ago | $28.23 | $1,214.31 | +21.4% |
| 6 months ago | $37.64 | $910.73 | -8.9% |
| 1 year ago | $32.06 | $1,069.25 | +6.9% |
| All time (5.0y) ago | $81.8 | $419.07 | -58.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ATRC forecast.
Our base-case forecast reaches $69.00 around 2031.
Implied market cap at $69.00: $3.49B
The multi-year forecast outlines a rising trajectory across years, driven by higher average prices and a bullish tilt in the later horizon. In 2026 the avg is $34.56 with ROI 0 and sentiment Neutral; 2027 avg $40.43 with ROI 17 and Neutral; 2028 avg $45.79 with ROI 32.5 and Bullish; 2029 avg $51.96 with ROI 50.4 and Bullish. By 2030 the avg is $57.20 with ROI 65.5 and Bullish, followed by 2031 avg $74.30 (ROI 115) and 2032 avg $84.98 (ROI 145.9).
2033 shows avg $90.68 (ROI 162.4), 2034 avg $101.81 (ROI 194.6), and 2035 avg $98.51 (ROI 185.1), all with Bullish sentiment.
The forecast extends to 2040, where the avg rises to $176.29 (ROI 410.1) with min $111.67 and max $299.79; and finally to 2050, with an avg of $348.03 (ROI 907), min $195.76, max $648.34, and Bullish sentiment. Annualized volatility is around 50%, underscoring substantial near-term risk alongside the strong longer-run upside. These figures are estimates, not guarantees, and reflect projected paths under varying conditions.
Tap a question to reveal the answer.
Average price $57.20; min $42.24; max $83.54; ROI 65.5; sentiment BULLISH.
Forecasts show potential upside with 2050 average $348.03 and ROI 907, but near-term performance is uncertain and not a guarantee. 2026 average is $34.56 with ROI 0 and Neutral sentiment.
Yes. The forecast for 2034 shows average $101.81, with min $70.15 and max $160.21, indicating the path to and beyond $100 in the forecast horizon.
Current price is $34.56 and market cap is $1.75B; the rank is 2160.
Low $28.76; High $41.53.
AtriCure, Inc. Community Discussion
0Share your AtriCure, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.